Role of MicroRNAs in Anxiety and Anxiety-Related Disorders

Murphy, Conor P.; Singewald, Nicolas

doi:10.1007/7854_2019_109

Cited by 26 publications

(31 citation statements)

References 187 publications

(209 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…77 For example, they regulate neuronal plasticity, learning and memory. 78 There is also increasing evidence that ncRNAs, especially miRNAs, are involved in the pathogenesis of neuropsychiatric disorders including ADs. 78 For example, experimental up-or down-regulation of candidate miRNAs associated with neurocircuits associated with anxiety can modulate anxietyrelated behavior in animal models of ADs.…”

Section: Rat Hippocampusmentioning

confidence: 99%

“…78 There is also increasing evidence that ncRNAs, especially miRNAs, are involved in the pathogenesis of neuropsychiatric disorders including ADs. 78 For example, experimental up-or down-regulation of candidate miRNAs associated with neurocircuits associated with anxiety can modulate anxietyrelated behavior in animal models of ADs. 77 Studies on animal models of ADs suggest that specific miRNAs may play various roles in the development and progression of anxiety in a brain region-specific manner.…”

Section: Rat Hippocampusmentioning

confidence: 99%

“…77 Studies on animal models of ADs suggest that specific miRNAs may play various roles in the development and progression of anxiety in a brain region-specific manner. 78 Transposable elements (TEs) are mobile genetic elements (pieces of DNA capable of moving to new locations). 79 They make up to two-thirds of the human genome.…”

Section: Rat Hippocampusmentioning

confidence: 99%

See 2 more Smart Citations

The Potential Role of Epigenetic Drugs in the Treatment of Anxiety Disorders

Peedicayil¹

2020

NDT

View full text Add to dashboard Cite

There is increasing evidence that abnormalities in epigenetic mechanisms of gene expression contribute to the pathogenesis of anxiety disorders (ADs). This article discusses the role of epigenetic mechanisms of gene expression in the pathogenesis of ADs. It also discusses the data so far obtained from preclinical and clinical trials on the use of epigenetic drugs for treating ADs. Most drug trials investigating the use of epigenetic drugs for treating ADs have used histone deacetylase inhibitors (HDACi). HDACi are showing favorable results in both preclinical and clinical drug trials for treating ADs. However, at present the mode of action of HDACi in ADs is not clear. More work needs to be done to elucidate how epigenetic dysregulation contributes to the pathogenesis of ADs. More work also needs to be done on the mode of action of HDACi in alleviating the signs and symptoms of ADs.

show abstract

Section: Rat Hippocampusmentioning

confidence: 99%

Section: Rat Hippocampusmentioning

confidence: 99%

See 1 more Smart Citation

The Potential Role of Epigenetic Drugs in the Treatment of Anxiety Disorders

Peedicayil¹

2020

NDT

View full text Add to dashboard Cite

show abstract

“…Recent studies show that miRNAs are significant biomarkers of schizophrenia, bipolar disorder, major depression and anxiety disorders. [19][20][21][22] That is why we consider the miRNome analysis in our study subjects as an integral and complementary part of genetic research.…”

Section: Introductionmentioning

confidence: 99%

Gene–Environment Interactions in Major Mental Disorders in the Czech Republic

Látalová

Šerý

Hosakova

et al. 2020

NDT

View full text Add to dashboard Cite

Background: Mental disorders affect about one-third of the human population, are typically chronic and significantly decrease the quality of life. Presently, the treatment of mental illnesses is far from adequate with a substantial proportion of the patients being pharmacoresistant and suffering from relapses. One of the reasons for this complicated situation is that we do not precisely know about the causes of mental disorders, so their treatment cannot be causal. The etiology of a mental disorder is typically based on a combination of molecular (genetic) and environmental factors. Aim: The aim of the project is to discover the gene-environment interactions (GxE) in a wide spectrum of mental disorders. Methods: The design of our study is innovative in the sense that we intend to study large groups of associated mental disorders as a whole instead of in isolation. This would enable us to map out the possible environmental causal factors in detail in relation to their character, magnitude and timing. The project also allows a study of genetics (including epigenetics and microbiomes) as well as the environment simultaneously. We plan on involving three study groups: the first group are patients suffering from schizophrenia or a mood disorder such as major depression, recurrent depressive disorder and bipolar affective disorder; the second group of patients have anxiety disorders; and the third group are healthy volunteers from the general population who are genetically unrelated. All of the study subjects will undergo the following assessments: a psychiatric examination, the identification of stressful life events with the aid of a questionnaire, the examination of their reaction to stress, genetic and epigenetic (microRNA) assessments and the analysis of oral and gut microbiome. Conclusion: We expect that some of the genetic as well as environmental factors in the studied mental disorders are shared, while some others are specific. We also expect that the GxE (gene-environment interaction) in schizophrenic and affective disorders will be different from the GxE in anxiety disorders and that the GxE in the studied mental disorders will differ generally from the GxE in healthy volunteers. Our results can help in the prevention and individualized treatment of a range of mental disorders.

show abstract

“…Recent studies have focused attention on the role of the microRNA system in the pathophysiology of psychiatric diseases [1][2][3][4]. However, our understanding of how microRNA signaling pathways operate normally in the nervous system is quite limited, making it difficult to assess how altered microRNA signaling may contribute to these disorders.…”

Section: Introductionmentioning

confidence: 99%

Increased amphetamine-induced hyperactivity intranslin (Tsn)KO mice is driven by elevated adiposity

Shah²,

Keighron³

et al. 2020

Preprint

View full text Add to dashboard Cite

The translin/trax microRNA-degrading enzyme mediates activity-induced changes in translation that underlie several long-lasting forms of cellular plasticity. As translin and trax are expressed in dopaminergic and striatal neurons, we investigated whether deletion of Tsn blocks amphetamine sensitization, a long-lasting, translation-dependent form of behavioral plasticity.Although we had hypothesized that constitutive Tsn deletion would impair amphetamine sensitization, we found, instead, that it enhances the hyperlocomotion produced by the initial dose of amphetamine. Since these mice display elevated adiposity, which alters pharmacokinetics of many drugs, we measured brain levels of amphetamine in Tsn knockout mice and found that these are elevated. As conditional Tsn deletion in adulthood does not impact adiposity, we monitored the locomotor response to amphetamine following this manipulation. Acute and sensitized responses to amphetamine are not altered in these mice, indicating that the enhanced amphetamine response displayed by constitutive Tsn knockout mice is due to Tsn absence during development.

show abstract

Role of MicroRNAs in Anxiety and Anxiety-Related Disorders

Cited by 26 publications

References 187 publications

<p>The Potential Role of Epigenetic Drugs in the Treatment of Anxiety Disorders</p>

<p>The Potential Role of Epigenetic Drugs in the Treatment of Anxiety Disorders</p>

<p>Gene–Environment Interactions in Major Mental Disorders in the Czech Republic</p>

Increased amphetamine-induced hyperactivity intranslin (Tsn)KO mice is driven by elevated adiposity

Contact Info

Product

Resources

About